TABLE 2.
Comparison of serum C reactive protein (CRP) levels and disease activity score based on CRP (DAS-28-CRP) between and within the study groups.
| Parameter | Metformin group n = 30 | Control group n = 30 | p-value |
|---|---|---|---|
| Serum CRP levels (mg/L) | |||
| Baseline, median (range) | 16 (3–30) | 12 (3–24) | 0.204b |
| After 3 months, median (range) | 12 (2–24) | 14 (3–26) | 0.207b |
| After 6 months, median (range) | 7 (2–36) | 15 (6–30) | <0.001a , b |
| p-value | <0.001a , c , d | 0.117c | |
| DAS-28-CRP | |||
| Baseline, median (range) | 5.47 (4.32–6.87) | 5.65 (3.68–6.85) | 1b |
| After 3 months, median (range) | 5.20 (3.36–6.66) | 5.65 (3.70–6.66) | 0.144b |
| After 6 months, median (range) | 4.79 (3.16–6.57) | 5.88 (4.3–6.8) | <0.001a , b |
| p-value | <0.001a , c , e | 0.465c | |
a
Indicates statistical significance (p-value <0.05).
b
Mann-Whitney test.
c
Friedman test.
d
Post-hoc tests (pairwise comparisons) revealed significance differences in CRP levels between baseline-after 3 months, baseline-after 6 months, and after 3 months-after 6 months.
e
Post-hoc tests (pairwise comparisons) revealed significance differences in DAS-28 between baseline-after 3 months, baseline-after 6 months, and after 3 months-after 6 months.